UCB

12 articles with UCB

• UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy

  1/13/2021

  UCB invested €25 million ($29.3 million) and as majority shareholder, will sit on the Board of Directors of Nile with future opportunities to acquire insights and data from Nile's platform

• UCB Demonstrates Commitment to Science and Discovery Across Its Epilepsy Portfolio at the American Epilepsy Society's Virtual Event AES2020

  12/4/2020

  UCB's VIMPAT, recently approved by the U.S. Food and Drug Administration (FDA) as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS), will be highlighted during virtual symposium featuring expert neurology panel

• UCB taps Medisafe in development of digital companion to support patient engagement

  11/23/2020

  Branded digital companions are available through Medisafe's advanced platform to UCB members currently enrolled in its antiepileptic drug therapy

• doc.ai and UCB Biopharma Team Up to Develop Breakthrough Artificial Intelligence Models to Advance Care

  11/19/2020

  New digital health trial will leverage state-of-the-art tech to detect and predict myasthenia gravis symptom patterns and flares

• UCB's VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy

  11/17/2020

  These approvals further help patients with epilepsy who may have had limited treatment options in the past, while reinforcing UCB's leadership in transforming epilepsy care

• UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms

  11/12/2020

  Acquisition of Handl Therapeutics BV augments UCB's existing early gene therapy pipeline with two research programs, a proprietary adeno-associated virus (AAV) capsid technology platform and capabilities

• 

  UCB Flexes M&A Muscles to Bolster its Gene Therapy Capabilities

  11/12/2020

  This morning, the company announced it bolstered its own gene therapy activities with the acquisition of Handl Therapeutics BV, a rapidly growing and transformative gene therapy company.

• UCB Presents Nine Abstracts at EADV 2020, Showcasing Ongoing Commitment to Dermatology

  10/29/2020

  - First results from the Phase 3 BE SURE study will be presented showing superior skin clearance with bimekizumab compared to Humira® (adalimumab) in patients with moderate-to-severe plaque psoriasis - Two oral presentations from the Phase 3 BE VIVID study show consistent levels of skin clearance with bimekizumab irrespective of patient demographics, disease characteristics and prior treatment experience, and an acceptable safety profile based on an integrated analysis across Phase 2 a

• 

  UCB Snags Eli Lilly U.K. Research Site, Plans to Invest £1 Billion Over Five Years for R&D

  10/16/2020

  UCB is investing more than £1 billion over five years to expand its research and development capabilities in the U.K., which will include a transition to a newly acquired 47-acre R&D campus from Eli Lilly located in Windlesham, Surrey.

• UCB Achieves Important Regulatory Milestone for Bimekizumab

  9/22/2020

  The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted marketing application submissions for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis

• Tennis Champion Caroline Wozniacki and UCB Launch Advantage Hers Campaign for Women with Chronic Inflammatory Diseases

  9/9/2020

  Grand Slam winner Caroline Wozniacki is the highest-ranking female athlete known to have been diagnosed with rheumatoid arthritis whilst still playing professional tennis

• 

  Clinical Catch-Up: August 31-September 4

  9/8/2020

  It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.